3 . 従来の注射型ワクチンでは病原体の侵入門戸に当る粘膜面での感染防御に制約があり、このため粘膜ワクチンの開発が進められている。そのための基盤的技術として、乳酸菌を送達体のベースにした新たな「飲むワクチン」(経口ワクチン)の可能性を小動物モデルで検討している(図 2 は、好酸球が DNA ワクチン送達標的であることを解明したもの)。
We study molecular pathogenesis of infectious diseases, host immune responses against infectious agents, and development of vaccines and antiviral compounds. The main on-going research projects are as follows:
1 . Congenital cytomegalovirus (CMV) infection occurs in 0.3% of all births, and causes birth defects and developmental abnormalities in Japan. Since saliva/urine of siblings is the major source of infection, it is essential to develop vaccines to protect pregnant women from infection. Using guinea pig models (Fig. 1 ), we evaluate strategies for CMV vaccine development. In addition, we study molecular mechanisms of viral infection, neurological pathogenesis, and viral evasion from host immune responses.
2 . We screen novel antiviral compounds that can be alternatives of the licensed drugs and analyze their inhibitory mechanisms. We also evaluate efficacy of ingredients of Foods with Function Claims against inflammation induced by bacterial or viral infections.
3 . We develop oral vaccine strategies based on lactic acid bacteria as carriers for antigens and DNA vaccines in small animal models (Fig. 2 shows that eosinophils are the main targets for oral DNA vaccine delivery using lactic acid bacteria).
研究課題 Research Objectives
サイトメガロウイルスの感染・発症機序、感染防御、ワクチン開発に関する研究 Pathobiological and immunological studies on cytomegalovirus infection and vaccine development.
新規抗ウイルス薬の探索と作用機序に関する研究 Screening of novel antiviral compounds and analyses of their inhibitory mechanisms.
乳酸菌を送達体とする経口ワクチンの開発に関する研究 Studies on oral vaccine strategies based on lactic acid bacteria in small animal models.
抗炎症効果を示す機能性食品成分に関する研究 Studies on the anti-inflammatory materials derived from functional foods.
最近の研究成果 Research Results
Sudo H, Tokunoh N, Tsujii A, Kawashima S, Hayakawa Y, Fukushima H, Takahashi K, Koshizuka T, Inoue N. The adjuvant effect of bacterium-like particles (BLPs) depends on the route of administration. Frontiers in Immunology 2023 14:1082273.
Satoh K, Takahashi K, Noguchi K, Kobayashi Y, Majima R, Iwase Y, Yamaguchi K, Masuda Y, Koshizuka T, Inoue N. Characterization of the second apoptosis inhibitor encoded by guinea pig cytomegalovirus. J. Virol. 2022 96(24):e0162222.
Minegaki N, Koshizuka T, Hatasa K, Kondo H, Kato H, Tannaka M, Takahashi K, Tsuji M, Inoue N. The C-terminal penta-peptide repeats of major royal jelly protein 3 ameliorate the progression of inflammation in vivo and in vitro.Biol Pharm Bull. 2022 45(5):583-589.
Characterization of a thiourea derivative that targets viral transactivators of cytomegalovirus and herpes simplex virus type 1. Antiviral Res. 2021 196:105207.
Takahashi K, Sugiyama T, Tokunoh N, Tsurumi S, Koshizuka T, Inoue N.
Intimate adhesion are essential for the pathogen-specific inflammatory and immune responses in the gut of mice infected with Citrobacter rodentium.Immunohorizons. 2021 5(10):870-883.